These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7541834)

  • 1. The treatment of intractable rejection with tacrolimus (FK506) in pediatric liver transplant recipients.
    McDiarmid SV; Wallace P; Vargas J; Ament ME; Busuttil RW
    J Pediatr Gastroenterol Nutr; 1995 Apr; 20(3):291-9. PubMed ID: 7541834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK506 conversion for intractable rejection of the liver allograft.
    McDiarmid SV; Klintmalm GB; Busuttil RW
    Transpl Int; 1993; 6(6):305-12. PubMed ID: 7507675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FK506 conversion therapy in pediatric liver transplantation.
    Egawa H; Esquivel CO; So SK; Cox K; Concepcion W; Lawrence L
    Transplantation; 1994 Apr; 57(8):1169-73. PubMed ID: 7513911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.
    McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P
    J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity versus rejection--or why conversions between cyclosporine A and FK506 were performed after liver transplantation.
    Platz KP; Mueller AR; Jonas S; Blumhardt G; Bechstein WO; Lobeck H; Neuhaus HL
    Clin Transplant; 1995 Jun; 9(3 Pt 1):146-54. PubMed ID: 7549052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S; Cox KL; Berquist W; Hayashi M; Concepcion W; Hammes GB; Ojogho OK; So SK; Frerker M; Castillo RO; Monge H; Esquivel CO
    Pediatr Transplant; 1999 Feb; 3(1):22-6. PubMed ID: 10359027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial.
    McDiarmid SV; Busuttil RW; Ascher NL; Burdick J; D'Alessandro AM; Esquivel C; Kalayoglu M; Klein AS; Marsh JW; Miller CM
    Transplantation; 1995 Feb; 59(4):530-6. PubMed ID: 7533345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation.
    Gruessner RW; Burke GW; Stratta R; Sollinger H; Benedetti E; Marsh C; Stock P; Boudreaux JP; Martin M; Drangstveit MB; Sutherland DE; Gruessner A
    Transplantation; 1996 Jan; 61(2):261-73. PubMed ID: 8600635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection.
    Reyes J; Jain A; Mazariegos G; Kashyap R; Green M; Iurlano K; Fung J
    Transplantation; 2000 Jun; 69(12):2573-80. PubMed ID: 10910279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
    Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
    Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients.
    Demetris AJ; Fung JJ; Todo S; McCauley J; Jain A; Takaya S; Alessiani M; Abu-Elmagd K; Van Thiel DH; Starzl TE
    Transplantation; 1992 May; 53(5):1056-62. PubMed ID: 1374944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from cyclosporine to FK506 in adult liver transplant recipients: a combined North American and European experience.
    Selzner N; Durand F; Bernuau J; Heneghan MA; Tuttle-Newhall JE; Belghiti J; Clavien PA
    Transplantation; 2001 Sep; 72(6):1061-5. PubMed ID: 11579301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine.
    Taler SJ; Textor SC; Canzanello VJ; Schwartz L; Porayko M; Wiesner RH; Krom RA
    Transplantation; 1996 Dec; 62(11):1588-92. PubMed ID: 8970613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Efficacy, toxicity, and dose regimen in 23 children.
    Reding R; Wallemacq PE; Lamy ME; Rahier J; Sempoux C; Debande B; Jamart J; Barker A; Sokal E; De Ville de Goyet J
    Transplantation; 1994 Jan; 57(1):93-100. PubMed ID: 7507272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants.
    Raofi V; Holman DM; Coady N; Vazquez E; Dunn TB; Bartholomew AM; Pollak R; Benedetti E
    Am J Surg; 1999 Apr; 177(4):299-302. PubMed ID: 10326847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience.
    Neuhaus P; Blumhardt G; Bechstein WO; Platz KP; Jonas S; Mueller AR; Langrehr JM; Lohmann R; Schattenfroh N; Knoop M
    Transplantation; 1995 Jan; 59(1):31-40. PubMed ID: 7530868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weaning of immunosuppression in liver transplant recipients.
    Mazariegos GV; Reyes J; Marino IR; Demetris AJ; Flynn B; Irish W; McMichael J; Fung JJ; Starzl TE
    Transplantation; 1997 Jan; 63(2):243-9. PubMed ID: 9020325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection.
    Millis JM; Woodle ES; Piper JB; Bruce DS; Newell KA; Seaman DS; Baker AL; Hart J; Dasgupta K; Thistlethwaite JR
    Transplantation; 1996 May; 61(9):1365-9. PubMed ID: 8629298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.